NCT02316834 - Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2015

Primary Completion Date

January 14, 2022

Study Completion Date

January 14, 2022

Conditions

Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaOvarian MassPrimary Peritoneal Serous AdenocarcinomaStage III Fallopian Tube Cancer AJCC v7Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIA Ovarian Cancer AJCC v6 and v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIB Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Ovarian Cancer AJCC v6 and v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

BMN 673

"BMN673 given at a dose of 1 mg orally once daily.~Participants begin taking BMN 673 tablets by mouth every day, starting on the day of scheduled laparoscopy. Participants take the study drug for at least 7 days before scheduled tumor reduction surgery."

Trial Locations (6)

77030

M D Anderson Cancer Center, Houston

77054

The Woman's Hospital of Texas, Houston

77058

MD Anderson Regional Care Center-Bay Area, Nassau Bay

77094

MD Anderson Regional Care Center-Katy, Houston

77384

MD Anderson Regional Care Center-The Woodlands, The Woodlands

77478

MD Anderson Regional Care Center-Sugar Land, Sugar Land

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER